Radionuclide treatment with Lutetium-177 [177Lu]-PSMA-617 nearly doubled median PSA progression-free survival in men with progressive metastatic castrate-resistant prostate cancer compared with previous results with radium-223.
Original Article: Novel Radionuclide Treatment Shows Promise in mCRPC